Eli Lilly (NYSE:LLY) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.